Document is current
Any future updates will be listed below
-
Authors
Poulsen, Adam https://orcid.org/0000-0002-0001-3894
Hickie, Ian B. https://orcid.org/0000-0001-8832-9895
Gorban, Carla https://orcid.org/0009-0003-9568-1792
de Haan, Zsofi https://orcid.org/0009-0003-3341-5982
Capon, William https://orcid.org/0000-0001-6500-9629
Eyeson-Annan, Ebenezer https://orcid.org/0009-0009-3526-0201
Radwan, Jalal https://orcid.org/0009-0005-2929-7252
Scott, Elizabeth M. https://orcid.org/0000-0003-3907-0324
Iorfino, Frank https://orcid.org/0000-0003-1109-0972
LaMonica, Haley M. https://orcid.org/0000-0002-6563-5467
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (GNT2016346)
National Health and Medical Research Council (GNT2018157)
- License Information
-
More Information
Article History
Received: 19 December 2025
Accepted: 3 June 2026
First Online: 19 June 2026
Competing interests
: I.B.H. is a Professor of Psychiatry and the Co-Director of Health and Policy, Brain and Mind Centre, University of Sydney. He has led major public health and health service development in Australia, particularly focusing on early intervention for young people with depression, suicidal thoughts and behaviours and complex mood disorders. He is active in the development through codesign, implementation and continuous evaluation of new health information and personal monitoring technologies to drive highly-personalised and measurement-based care. He holds a 3.2% equity share in Innowell Pty Ltd that is focused on digital transformation of mental health services. E.M.S. is a Principal Research Fellow at the Brain and Mind Centre, University of Sydney, a Consultant Psychiatrist and Adjunct Clinical Professor at the School of Medicine, University of Notre Dame. She previously served as the Discipline Leader for Adult Mental Health at Notre Dame until January 2025. In addition, she is a member of Medibank’s Medical and Mental Health Reference Groups. E.M.S. has also delivered educational seminars on the clinical management of depressive disorders, receiving honoraria from pharmaceutical companies including Servier, Janssen, and Eli Lilly. Moreover, she has contributed to a national advisory board for Pfizer’s antidepressant Pristiq and served as the National Coordinator for an antidepressant trial sponsored by Servier. A.P., C.G., Z.H., W.C., E.E-A., J.R., E.M.S., F.I., and H.M.L. have nothing to disclose.
